The Bank of Japan raised its key interest rate by 25 basis points to 1.25% on September 18, 2026, marking the highest level in 31 years. Despite this tightening, the yen weakened against the US dollar, which prevented the typical unwinding of yen-funded leveraged positions that often pressures crypto prices. The interest rate gap between Japan (1.25%) and the US (3.75-4.00%) remains wide, sustaining the carry trade that supports crypto assets. Investors should monitor the yen exchange rate and leverage risks, as further rate moves and currency shifts could impact crypto markets in the coming weeks.
The yen carry trade context includes a wide interest rate gap between Japan at 1.25% and the US at 3.75-4.00%. For readers following this topic, here is Pluang's market snapshot as of Sep 19, 2026 06:51 WIB: out of 50 major cryptocurrencies, 43 rose and 6 fell today. Notable movers include Ethereum Classic (ETC) with a 10.08% increase and a typical hold time of 67 days, Bitcoin Cash (BCH) up 9.07% with a 68-day hold, and Compound (COMP) rising 8.66% with a 97-day hold and 100% buy order activity on Pluang.
The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...
Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...
China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...
Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...
Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...
